borderline significanceP = 0.051
Nevertheless, borderline significance ( P = 0.051) was achieved in favor of candesartan in the CHARM study after prespecified adjustments for covariates.
Nevertheless, borderline significance ( P = 0.051) was achieved in favor of candesartan in the CHARM study after prespecified adjustments for covariates.
Although PEP-CHF did not enroll the planned number of participants, the 1-year interim analysis showed a borderline significant effect on the primary endpoint, a composite of mortality and hospitalization for HF worsening.